Aino Health AB (publ): The Offer in Aino Health AB (publ) heavily oversubscribed
December 9, 2016
NOT FOR DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, TO NEWS DISTRIBUTORS IN THE UNITED STATES, OR FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION OR PUBLICATION WOULD NOT BE ALLOWED BY APPLICABLE LAW.
Aino Health AB (publ) ("Aino Health" or the "Company") has completed the Offer to the market to subscribe for shares in the Company for a total of 53.8 MSEK (the "Offer"), distributed on a share issue of 46.8 MSEK (the "Share Issue") and an Over-allotment of existing shares of 7.0 MSEK for stabilization activities (the "Over-allotment"). The Over-allotment including stabilization of the share price during 30 calendar days may imply that Aino Health will receive an addition of 7.0 MSEK through a share issue included in the Over-allotment option directed to Erik Penser Bank AB, after which the Company would receive up to 48.8 MSEK.
The Offer attracted strong interest and was subscribed to about 206 percent, equivalent to 2.1 times the Offer. Due to the strong interest shares have been allocated to around 1 100 new shareholders among almost 4 000 applicants. First day of trading Aino Health's shares is scheduled for Friday December 16, 2016.
November 27, 2016, the Board of Directors in Aino Health published the decision to apply for listing of the Company's shares on Nasdaq First North, and in connection with the listing the Board of Directors decided to diversify the ownership through a Share Issue according to the Offer. The Offer consists of 1,800,000 newly issued shares and an Over-allotment of 270,000 existing shares as a part of the stabilization of the share price during 30 calendar days. The Company may receive an addition of 270,000 shares through the Over-allotment option directed to Erik Penser Bank as a part of the agreed stabilization of the share price.
The number of shares will increase from 3,622,770 to 5,422,770 through the Share Issue and up to 5,692,770 shares if the Over-allotment is fully exercised. The dilution for existing shareholders amounts to 33.2 percent and to a maximum of 36.2 percent if the Over-allotment option is fully exercised.
The Offer implies that the Company will be added around 1 100 new shareholders, after which the total number of shareholders will amount to approximately 1 200. The Company will meet the share distribution requirements on Nasdaq First North and the first day of trading is scheduled for Friday December 16, 2016.
The subscription period for the Offer expired on Thursday, December 8, 2016. A number of institutional partners and private investors have, before the initiated subscription period, undertaken to subscribe for shares in the Share Issue corresponding to approximately 31.9 MSEK, or about 86 percent of the Share Issue.
The Board of Directors in Aino Health has, in consultation with Erik Penser Bank, decided on the allotment of shares in the Offer, in which the objective has been to achieve a good distribution of the share to enable a regular and liquid trading on Nasdaq First North as well as achieving a desired strategic ownership base. The allotment decision will be obtained in the form of a contract note. Information will not be sent to those who have not been allotted shares.
After the Offer has been registered at the Swedish Companies Registration Office the total number of shares in Aino Health will increase by 1,800,000 shares from 3,622,770 shares to 5,422,770 shares. The share capital will increase by 4,500,000 SEK to 13,556,925 SEK. If the Over-allotment option is fully exercised, this implies an additional increase of 270,000 shares and an increase of the share capital of 675,000 SEK to 14,231,925 SEK.
"We are very pleased with the great interest we have had in Aino Health's IPO. While we have secured capital for our expansion into Europe with focus on Sweden and Germany as the first countries, we have received a large number of new shareholders. We are very happy for this and the legitimacy that our listing gives in various customer contacts", says Jyrki Eklund, CEO of Aino Health
Erik Penser AB is the financial advisor and Advokatfirman Lindahl KB is the legal adviser in the Offer and listing on Nasdaq First North. Erik Penser AB is Certified Adviser to the Company.
Publication and distribution of this press release may in certain jurisdictions be restricted by law and persons in those jurisdictions where this press release has been published or distributed should inform themselves about and follow such restrictions. The information in this press release is not an offer to acquire, subscribe for or otherwise trade in shares or another security in Aino Health.
This press release may not be released, published or distributed, directly or indirectly, in or into the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Singapore, South Africa or another country where such action requires further measures in addition to what follows from Swedish law or where this would contravene with laws or regulations of that country. The information in this press release may not be forwarded, reproduced or disclosed in ways that conflict with such restrictions. Omission to follow this instruction may constitute a violation of the United States Securities Act of 1933 (the "Securities Act") in its present terms or applicable laws in other jurisdictions.
This information is such information that Aino Health AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at December 9 CET on 8:30 2016.
or more information, please contact:
Jyrki Eklund, CEO
Phone: +358 40 042 4221
Cecilia Hollerup, Chairman of the Board of Directors
Phone: +46 70 829 33 36
About Aino Health
Aino Health operates within Corporate Health Management. The company has developed a complete system of IT-based services with a focus to improve corporate health and reduce sickness absence levels in private and public organizations.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Aino Health AB (publ) via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
SD-WAN for Office 365: Aryaka Helps eLearning company, City & Guilds Group, Improve Office 365 Application Response Time19.4.2018 18:54 | Pressmeddelande
Aryaka's Global SD-WAN reduces time for global users to open SharePoint files from 10 to 0.05 seconds; Outlook performance improves 9x worldwide LONDON, April 19, 2018 (GLOBE NEWSWIRE) -- Aryaka®, the leading global SD-WAN provider, announced today its SD-WAN technology has enabled City & Guilds Group, a worldwide leader in workplace skills, eLearning, and executive coaching, to achieve faster Office 365 application response times leading to an increase in productivity and better collaboration between users in Europe and Asia-Pacific. Headquartered in London, the City & Guilds Group works with education providers, governments and major corporations to help shape and support skills development for employers in over 100 countries. Team members of the company are similarly scattered around the world and primarily collaborate using Microsoft Office 365 applications, but many remote users were struggling to access the group's instance of Office 365 hosted in Dublin. For example, it could ta
Canacol Energy Ltd. Announces Private Offering of Senior Notes19.4.2018 16:23 | Pressmeddelande
CALGARY, Alberta, April 19, 2018 (GLOBE NEWSWIRE) -- Canacol Energy Ltd. ("Canacol" or the "Corporation") (TSX:CNE) (OTCQX:CNNEF) (BVC:CNEC) is pleased to announce that it intends, subject to market and other conditions, to offer senior unsecured notes (the "Notes") in a private placement to qualified institutional buyers in the United States pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"), to non-U.S. persons in transactions outside the United States pursuant to Regulation S under the Securities Act and pursuant to certain prospectus exemptions in Canada (the "Offering"). The Notes will be fully and unconditionally guaranteed by certain subsidiaries of Canacol. The interest rate, redemption prices and other terms of the Notes are to be determined upon pricing of the Offering. Canacol intends to use the net proceeds from the Offering: (i) to repay the outstanding amounts borrowed under its credit facility; (ii) to pay fees and expenses of the O
FinancialForce Extends Professional Services Automation Leadership With its Spring 2018 Release19.4.2018 14:00 | Pressmeddelande
New features empower services organizations to run their businesses with greater predictability, assign best-fit resources at scale, and forecast projects with 360-degree insight. SAN FRANCISCO, April 19, 2018 (GLOBE NEWSWIRE) -- FinancialForce, the number one customer-centric ERP cloud vendor built on the Salesforce Platform, announced the availability of its latest version of Professional Services Automation, the highest customer-rated PSA solution for enterprise organizations. The Spring 2018 Release of PSA brings new functional capabilities to accelerate project staffing speed and accuracy; unify people and project data; enable better forecasting decisions; and enhance the overall user experience using the Salesforce Lightning framework. Fast, Accurate Resource Mapping With the Spring 2018 Release of PSA, project and resource managers can identify and assign best-fit resources with greater speed and accuracy. Through advanced skills filtering and search capabilities, including part
SpeeDx receives FDA clearance for Mycoplasma genitalium product19.4.2018 14:00 | Pressmeddelande
SYDNEY, Australia, April 19, 2018 (GLOBE NEWSWIRE) -- SpeeDx's Resistance Plus ® MG Positive Control kit has now been listed with the US Food and Drug Administration (FDA) for sale in the United States through the company's recently incorporated US entity, SpeeDx Inc. The announcement coincides with the FDA registration of the Australian parent company - SpeeDx Pty Ltd - as a Medical Device Manufacturing Establishment, and clinical trials remain on-track for the Resistance Plus MG assay.* The Resistance Plus MG Positive Control kit contains synthetic DNA to simulate Mycoplasma genitalium, as well as five mutations known to confer resistance to macrolide antibiotics. Macrolide-resistant M. genitalium is a challenging sexually transmitted infection (STI), and global management guidelines are currently being adapted to deal with the rise in resistance. "This is an important product in our portfolio," said Elisa Mokany, Chief Technology Officer for SpeeDx. "M. genitalium is very difficult
Cisco ACI Is Data Center Solution of Choice for Service Providers Worldwide19.4.2018 14:00 | Pressmeddelande
Service providers deliver new cloud services more quickly and offer superior customer experience with the help of Cisco Application Centric Infrastructure SAN JOSE, Calif., April 19, 2018 (GLOBE NEWSWIRE) -- Providing secure, differentiated and rapidly delivered cloud services to customers is a crucial requirement for today's service providers. To meet cloud infrastructure demands, global service providers are increasingly turning to the Cisco® Application Centric Infrastructure (Cisco ACI(TM)) , the industry-leading software-defined networking (SDN) solution. Cisco ACI reduces operational costs with an automated, policy-based programmable architecture, while improving scalability and security. In addition, new Cisco ACI multi-site management capability helps service providers to connect and manage multiple geographically distributed Cisco ACI fabrics and to move and manage workloads with a single pane of glass. Cisco ACI is being deployed worldwide by service providers such as NTT Com
Taconic Biosciences Launches New Inflammatory Bowel Disease Models19.4.2018 14:00 | Pressmeddelande
RENSSELAER, N.Y., April 19, 2018 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing genetically engineered mouse model and service solutions, announces the launch of several new inflammatory bowel disease (IBD) animal models. As a fully-licensed provider of CRISPR/Cas9 gene editing technology, Taconic scientists knocked out the mouse Il10 gene to generate a spontaneous colitis mouse models. The new knockout models were created on Taconic's B6 (C57BL/6NTac) and BALB/c (BALB/cAnNTac) backgrounds, and are available at both the Excluded Flora (EF) and Germ Free (GF) health standards. Beyond the scientific benefits, Taconic is also making them easy to access by offering these models to commercial, contract research organization (CRO), and academic institutions under a simple label license. This represents a departure from the license requirements for Il10 knockouts from other animal model providers. "In order for animal models to drive drug discovery they need to be both
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum